Objective:To explore the effect of insulin degludec/liraglutide in diabetic kidney disease(DKD)patients with poor glycemic control and its effect on serum inflammatory factors.Methods:A retrospective analysis was conducted on the clinical data of 96 DKD patients with poor glycemic control.Patients were divided into two groups based on treatment methods:the control group(n=48)received insulin glargine and insulin aspart,and the observation group(n=48)received insulin degludec/liraglutide for a course of 3 months.Blood glucose indicators[fasting plasma glucose(FPG),glycated hemoglobin(HbA1c),mean amplitude of glycemic excur-sions(MAGE),and largest amplitude of glycemic excursions(LAGE)],insulin function indicators[homeostatic model assessment for insulin resistance(HOMA-IR),homeostatic model assessment for β-cell function(HOMA-β)],serum inflammatory factors[interleu-kin-6(IL-6),serum amyloid A(SAA)],and renal function indicators[estimated glomerular filtration rate(eGFR),urine albumin-to-creatinine ratio(UACR)]were compared between the two groups.The incidence of adverse reactions was also recorded.Results:After treatment,FPG,HbA1c,MAGE,LAGE,HOMA-IR,serum IL-6,SAA levels and UACR all decreased in both groups(P<0.05),and the MAGE,LAGE,HOMA-IR,serum IL-6,SAA,and UACR levels in observation group were lower than those in control group(P<0.05).HOMA-β and eGFR increased in both groups(P<0.05),and HOMA-β in observation group was higher than that in control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Insulin degludec/liraglutide can better reduce blood glucose fluctuations in DKD patients with poor glycemic control,regulate insulin function,reduce serum inflammatory factor levels,and alleviate proteinuria in the short term.Improvement in eGFR still requires confirmation through long-term,large-sample studies.The safety profile is acceptable,but attention should be paid to the occurrence of hypoglycemia.